PCBL Chemical Limited (NSE:PCBL)
India · Delayed Price · Currency is INR 400.50
+6.50 (1.65%)
Aug 1, 2025, 3:30 PM IST
Inozyme Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 4,346 | 4,909 | 4,418 | 4,260 | 3,136 | Upgrade |
Depreciation & Amortization | - | 3,457 | 2,170 | 1,366 | 1,207 | 1,098 | Upgrade |
Other Amortization | - | - | 2.2 | 1.1 | 1.9 | 3.6 | Upgrade |
Loss (Gain) From Sale of Assets | - | -31.9 | -2.9 | 0.2 | 3.9 | -14.1 | Upgrade |
Loss (Gain) From Sale of Investments | - | -155.5 | -148.8 | -195.1 | -94.7 | 29.7 | Upgrade |
Provision & Write-off of Bad Debts | - | 1.1 | -3 | 1.1 | - | 8.3 | Upgrade |
Other Operating Activities | - | 4,064 | 1,208 | 180.6 | 169.9 | 212.2 | Upgrade |
Change in Accounts Receivable | - | -804.6 | -3,229 | -76.5 | -3,942 | -1,235 | Upgrade |
Change in Inventory | - | -2,688 | -1,440 | 325.2 | -1,591 | -1,187 | Upgrade |
Change in Accounts Payable | - | -1,978 | 6,930 | 532.1 | 3,172 | 1,667 | Upgrade |
Change in Other Net Operating Assets | - | 1,396 | 658.7 | -1,512 | -283.2 | 130.6 | Upgrade |
Operating Cash Flow | - | 7,605 | 11,054 | 5,041 | 2,904 | 3,850 | Upgrade |
Operating Cash Flow Growth | - | -31.20% | 119.29% | 73.57% | -24.57% | -27.64% | Upgrade |
Capital Expenditures | - | -7,738 | -5,358 | -8,959 | -3,062 | -1,155 | Upgrade |
Sale of Property, Plant & Equipment | - | 94.6 | 28.6 | 2 | - | 14.1 | Upgrade |
Cash Acquisitions | - | - | -37,080 | - | - | - | Upgrade |
Investment in Securities | - | 546.8 | 128.8 | 3,322 | -2,490 | -983.1 | Upgrade |
Other Investing Activities | - | 193.6 | 138.9 | 115.6 | 145.1 | 97.2 | Upgrade |
Investing Cash Flow | - | -6,903 | -42,141 | -5,519 | -5,407 | -2,027 | Upgrade |
Short-Term Debt Issued | - | 33,957 | 18,087 | 10,550 | 9,334 | 10,889 | Upgrade |
Long-Term Debt Issued | - | 5,480 | 39,559 | 3,100 | 1,200 | 2,350 | Upgrade |
Total Debt Issued | - | 39,437 | 57,646 | 13,650 | 10,534 | 13,239 | Upgrade |
Short-Term Debt Repaid | - | -27,465 | -17,860 | -10,100 | -8,155 | -11,616 | Upgrade |
Long-Term Debt Repaid | - | -6,907 | -2,247 | -1,247 | -1,897 | -1,853 | Upgrade |
Total Debt Repaid | - | -34,372 | -20,107 | -11,346 | -10,052 | -13,469 | Upgrade |
Net Debt Issued (Repaid) | - | 5,065 | 37,538 | 2,304 | 481.5 | -230 | Upgrade |
Issuance of Common Stock | - | 1,161 | - | - | 4,000 | - | Upgrade |
Common Dividends Paid | - | -2,076 | -2,076 | -2,076 | -1,887 | -1,206 | Upgrade |
Other Financing Activities | - | -4,790 | -1,655 | -533.5 | -427.2 | -359 | Upgrade |
Financing Cash Flow | - | -639.3 | 33,808 | -305.7 | 2,167 | -1,795 | Upgrade |
Net Cash Flow | - | 62.4 | 2,721 | -784.2 | -335.8 | 28 | Upgrade |
Free Cash Flow | - | -133.3 | 5,697 | -3,918 | -157.8 | 2,695 | Upgrade |
Free Cash Flow Growth | - | - | - | - | - | -10.56% | Upgrade |
Free Cash Flow Margin | - | -0.16% | 8.87% | -6.79% | -0.36% | 10.13% | Upgrade |
Free Cash Flow Per Share | - | -0.35 | 15.09 | -10.38 | -0.44 | 7.82 | Upgrade |
Cash Interest Paid | - | 4,751 | 1,655 | 533.5 | 328.3 | 359 | Upgrade |
Cash Income Tax Paid | - | 1,780 | 2,156 | 1,658 | 1,036 | 660 | Upgrade |
Levered Free Cash Flow | - | -4,172 | -2,090 | -3,612 | -1,468 | 1,906 | Upgrade |
Unlevered Free Cash Flow | - | -1,291 | -981.81 | -3,279 | -1,290 | 2,109 | Upgrade |
Change in Net Working Capital | - | 3,204 | 2,620 | -698.8 | 2,626 | 350.9 | Upgrade |
Updated Jan 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.